HHLA2 and intrahepatic cholangiocarcinoma: Additionally, higher HHLA2 levels correlated with higher CEA levels in the serum of patients with ICC and with the expression of CD73—another potential immuno-therapeutic target whose expression is associated with poorer OS and immunosuppression in ICC [13,78].